Can an old drug make immunotherapy work again for hodgkin lymphoma?

NCT ID NCT05162976

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding an oral chemotherapy drug (CC-486) to the immunotherapy nivolumab can help patients with Hodgkin lymphoma whose cancer no longer responds to PD-1 blockers. About 33 adults will receive the combination to find the safest dose and see if tumors shrink. The goal is to overcome resistance to standard immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral azacitidine (CC-486) plus nivolumab
What this could lead to: If it works, this combination could restore the effectiveness of nivolumab for patients whose Hodgkin lymphoma no longer responds to PD-1 therapy alone.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing. It may not show meaningful tumor shrinkage, and side effects from combining these drugs are not yet well understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT CLASSIC HODGKIN LYMPHOMA REFRACTORY CLASSIC HODGKIN LYMPHOMA

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.